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Background: Lumefantrine and atovaquone are highly lipophilic anti-malarial drugs. As a consequence absorption
is increased when the drugs are taken together with a fatty meal, but the free fraction of active drug decreases in
the presence of triglyceride-rich plasma lipoproteins. In this study, the consequences of lipidaemia on anti-malarial
drug efficacy were assessed in vitro.
Methods: Serum was obtained from non-immune volunteers under fasting conditions and after ingestion of a high
fat meal and used in standard Plasmodium falciparum in-vitro susceptibility assays. Anti-malarial drugs, including
lumefantrine, atovaquone and chloroquine in five-fold dilutions (range 0.05 ng/ml – 1 ug/mL) were diluted in
culture medium supplemented with fasting or post-prandial 10% donor serum. The in-vitro drug susceptibility of
parasite isolates was determined using the 3H-hypoxanthine uptake inhibition method and expressed as the
concentration which gave 50% inhibition of hypoxanthine uptake (IC50).
Results: Doubling plasma triglyceride concentrations (from 160 mg/dL to 320 mg/dL), resulted in an approximate
doubling of the IC50 for lumefantrine (191 ng/mL to 465 ng/mL, P< 0.01) and a 20-fold increase in the IC50 for
atovaquone (0.5 ng/mL to 12 ng/ml; P< 0.01). In contrast, susceptibility to the hydrophilic anti-malarial chloroquine
did not change in relation to triglyceride content of the medium.
Conclusions: Lipidaemia reduces the anti-malarial activity of lipophilic anti-malarial drugs. This is an important
confounder in laboratory in vitro testing and it could have therapeutic relevance.
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Malaria remains one of the most important diseases in the
tropical world. The main threat for malaria control is the
emergence and spread of insecticide resistance in vector
mosquitoes and anti-malarial drug resistance in malaria
parasites. Resistance of Plasmodium falciparum to chloro-
quine and sulphadoxine-pyrimethamine arose in SE Asia
and has spread subsequently to Africa resulting in the
deaths of millions of children [1,2]. Resistance of Plasmo-
dium vivax to chloroquine and pyrimethamine has also* Correspondence: nickw@tropmedres.ac
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distribution, and reproduction in any mediumbeen reported in many parts of the world [3–7]. An im-
portant driver for both the emergence and spread of anti-
malarial drug resistance is underdosing of anti-malarials
[8]. Underdosing in young children and pregnant women
is common, because blood concentrations of several anti-
malarial drugs are significantly lower compared to those
in non-pregnant adults [9]. Deployment of substandard
quality or counterfeit drugs is another important contribu-
tor, although difficult to quantify [10]. Pharmacokinetic
variability is a major confounder resulting in low plasma
concentrations despite taking the correct dose of a quality
assured drug.
Anti-malarial drugs bind variably to plasma constitu-
ents and blood cells. Partioning of drugs in the blood
may affect their access to malaria parasites. Atovaquonentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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malarial drugs. They are used as fixed dose combinations
as atovaquone-proguanil and artemether-lumefantrine, re-
spectively. Atovaquone-proguanil is used mainly as a
chemoprophylactic [11] and artemether-lumefantrine is
the most widely used artemisinin combination treatment
of uncomplicated falciparum malaria.
Atovaquone is a hydroxynaphthoquinone, with a parti-
tion coefficient (log P) of 5.1. When given alone it rap-
idly leads to drug resistance, since single point
mutations in the cytochrome B gene of P. falciparum
can confer up to a 10,000 fold reduction in sensitivity to
the drug [12]. Atovaquone is, therefore, only deployed in
combination with proguanil (Malarone R), which has a
synergistic effect with atovaquone and also provides
some protection against the emergence of drug
resistance.
Lumefantrine is an aryl-aminoalcohol, with a similar
mechanism of action to that of quinine, mefloquine, and
halofantrine. It is highly lipophilic with very high (98%)
binding to lipoproteins and fat in plasma. Absorption of
atovaquone and lumefantrine are both increased when
the drugs are taken with fat, which is the current recom-
mendation [13-16].
However, the increase in drug absorption with a fatty
meal might be offset, at least temporarily, by a reduction
in the free fraction of the plasma concentration of the
drug since the fatty meal will increase the concentration
of plasma lipids leading to increased drug partitioning to
the plasma fraction. It is not known whether this has
pharmacodynamic consequences. Whether the parasiti-
cidal activity of these lipophilic anti-malarial drugs might
be affected by the concentration of lipids present in the
culture medium was therefore investigated.Methods
This study was approved by the Ethics committee of the
Faculty of Tropical Medicine, Mahidol University
(MUTU2006-032). Written informed consent forms
were signed by the volunteers as well as patients before
recruitment into this study.Serum preparation
Blood (20 mL) was taken from three healthy volunteer
subjects (N= 3) after an overnight fast and also at 2 and
4 hours after consuming a meal containing more than
50g fat (a Mac Donald’s BigMac and a tall portion of
French fries). Blood samples were centrifuged at 800 g
for 5 minutes. Serum was collected, inactivated at 56°C
in a water bath and kept at 30°C until use. Triglyceride
levels in serum and in the culture medium were deter-
mined by an automated biochemical analyser (Cobas
501, Rocse. Switzerland).Preparation of drugs
Triplicate 96 well plates, pre-coated with anti-malarial
drugs were prepared as follows: lumefantrine (1 mg/mL
in linoleic acid: 100% ethanol, 1:1) and atovaquone
(1 mg/mL in 100% ethanol) in five-fold dilutions (range
0.05 ng/ml – 1 μg/mL) as described previously [17,18].
Drugs were diluted in culture medium supplemented
with fasting or post-prandial 10% donor serum. The
hydrophilic anti-malarial chloroquine (range 0.05 ng/ml –
1 μg/mL) was used as a negative control.
In vitro efficacy assessment
Plasmodium falciparum laboratory strain (TM267 from
Thailand) and ten P. falciparum parasites isolated from
patients who visited Mae Sot Hospital, Tak, Thailand, were
cultured using standard procedures [19]. In vitro drug sen-
sitivity testing also followed standard methods. Briefly,
each well contained an aliquot (100 μL) of culture, and
100 μL of red cell suspension (final haematocrit 5%) with
a 1% ring stage parasitaemia. Parasites were incubated at
37°C and 5% CO2 for 24 hours, after which 85 μL of
medium was removed and refreshed by replacement of an
equal volume of anti-malarial drug supplemented
medium. 3H-hypoxanthine (stock= 1 millicurie/mL) was
added to obtain a final dilution at 100 microcurie/mL.
After 48 hours of further incubation, cells were harvested
and incorporation of hypoxanthine was assessed in a beta-
counter. The level of hypoxanthine uptake was deter-
mined as a measure of schizont development. The 50% in-
hibitory concentration (IC50), (the concentration which
gave 50% inhibition of hypoxanthine uptake) was calcu-
lated from the sigmoid fitted curve, using Winnonlin
computer software version 5.3 (Pharsight, USA). The IC50
values between experimental conditions were compared
using the Mann- Whitney U Test. Correlations between
the IC50 and triglyceride concentrations in the culture
medium were calculated according to the methods of
Pearson and Spearman.
Results
The mean (SE) serum triglyceride levels (N=3) were 106
(29) mg/dL when fasting, and 200 (15) and 377 (25) mg/dL
at 2 and 4 hours after the high fat meal, respectively.
Addition of post-prandial serum markedly reduced the
in vitro activity of both drugs. There was an approximately
linear correlation between the triglyceride concentrations
of the added serum and the IC50 for both lumefantrine
(R=0.95, P< 0.01) and for atovaquone (R=0.96, P< 0.01)
(Figure 1). Ten parasite isolates were obtained for in-vitro
drug susceptibility assessment. With a two fold increase in
serum triglyceride concentrations (from 106 mg/dL to
200 mg/dL), there was an approximate two-fold increase in
the IC50 for lumefantrine (191 ng/mL to 465 ng/mL,
P< 0.01) and a 20-fold increase in the IC50 for
Figure 1 In-vitro drug susceptibility of Thai laboratory strain (TM267) to lumefantrine and atovaquone under culture conditions with
varying concentrations of triglycerides (TG) in the supplemented serum (10% v/v). Figure a: IC50 for lumefantrine (ng/mL); figure b: IC50 for
atovaquone (ng/mL).
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contrast, the parasiticidal efficacy of the hydrophilic
drug chloroquine was unaffected by the triglyceride
concentration of the serum added to the culture
medium (Table 1).
Discussion
The in vitro anti-malarial drug activitiesof lumefantrine
and atovaquone depend on the concentrations of lipid in
the culture medium. The lack of any effect of post-
prandial serum on the in vitro activity of chloroquine
argues against any non-specific anti-malarial effect
related to the high protein high fat meal. The decrease
in anti-malarial drug activity of atovaquone and lume-
fantrine in the presence of triglyceride rich lipoproteins
presumably reflects increased partitioning to thisTable 1 50% Inhibition concentrations (IC50) (ng/mL) of
lumefantrine, atovaquone and chloroquine under
different culture conditions: using medium supplemented
with 10% serum obtained from a fasting donor (‘fasting’)
or obtained 2 hours after ingestion of a fatty meal
(‘2hours’)
Drug Serum used IC50 (ng/mL)
in culture medium (Mean± SD)
Lumefantrine fasting 191 ± 53
2 hours 465 ± 34*
Atovaquone fasting 0.5 ± 0.3
2 hours 12 ± 6*
Chloroquine fasting 94 ± 39
2 hours 94 ± 14
Data of three replicate measurements of the same parasites (N = 10)
* P<0.005 when compared to fasting.fraction and a reduced unbound fraction of the lipophilic
drugs available to access the parasitized erythrocyte.
Increased partitioning to the lipid fraction therefore
reduced biological activity. Similar results have been
reported for halofantrine, which is also highly lipophilic
[20]. The administration of halofantrine with food
increases its absorption, and may lead to excessively high
plasma halofantrine concentration and cardiac toxicity
[21]. Acute malaria also induces changes in plasma lipo-
protein profiles [22]. These factors may affect the phar-
macokinetic and the pharmacodynamic profiles of these
lipophilic anti-malarial drugs.
Artemether-lumefantrine is highly effective treatment
of multi-drug resistant falciparum malaria [23,24] and
has become the most widely used ACT in the world.
Both artemether and lumefantrine absorbtion are
increased by fats although the effect on lumefantrine is
greater. As a result it is recommended that lumefantrine
should be taken together with fat, although a relatively
small quantity (1.2 g) is necessary to achieve 90% of the
maximum effect [16]. As the initial anti-parasitic effects
are mediated mainly by the artemether component,
these findings of reduced lumefantrine activity in lipae-
mic blood are unlikely to be of therapeutic relevance to
the initial response. However anti-malarial efficacy dur-
ing the terminal elimination phase, when plasma con-
centrations of the lumefantrine are low and patients
resume their normal diet, may be affected by dietary fat
intake. For atovaquone-proguanil, which is mainly used
as a prophylactic drug, efficacy in hyperlipidaemic travel-
lers might be compromised. The transient elevations in
triglycerides that follow meals are unlikely to affect anti-
malarial activity greatly. The reduction in anti-malarial
activity would be greatest in patients with persistently
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common in travelers such as hyperlipoproteinaemia, dia-
betes, and the metabolic syndrome. Patients receiving
anti-retroviral drugs may also have sustained hypertrigly-
ceridaemia and they too might have anti-malarial effi-
cacy compromised. Conversely atorvastatin, which is
widely used in the treatment of hypercholesterolaemia,
has significant anti-malarial properties [25]. Further
studies to determine the therapeutic relevance of these
observations are warranted.
Conclusions
In vitro tests are used to monitor anti-malarial drug sus-
ceptibility. These data suggest that post-prandial or
hyperlipidaemic blood or serum samples may not be ap-
propriate for in vitro testing of lipophilic anti-malarials.
Lipidaemia may contribute to variance in susceptibility
testing and confound assessments of resistance.
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